Erasca Finalizes $225M Public Offering at $10.00/Share
ERAS has more than doubled off its 52-week low of $1.01 on elevated volume (2.7× avg).
Summary
Erasca has priced its upsized public offering of 22.5 million shares at $10.00 per share, with expected gross proceeds of $225 million. The offering, which finalizes terms announced on January 20, 2026, will fund research and development efforts.
Key Events · Financing and Capital Events · ERAS
-
Public Offering Priced
Erasca priced its public offering of 22.5 million shares at $10.00 per share, raising $225 million in gross proceeds.
-
Underwriting Agreement
The company entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C.
-
Use of Proceeds
Erasca intends to use the net proceeds to fund research and development, working capital, and other general corporate purposes.
Analysis · ERAS · Life Sciences
Erasca has finalized the terms of its public offering, initially announced on January 20, 2026. The offering consists of 22.5 million shares at $10.00 per share, raising $225 million before deductions. This capital raise strengthens Erasca's balance sheet, providing resources for ongoing research and development.
At the time of this filing, ERAS was trading at $10.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $1.01 to $10.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.